tirzepatide breastfeeding Alexandra Sowa, MD | A big win for women's health: low-dose (2.5mg + 5mg) has now been deemed safe in breastfeeding. 🍼✨ is vital for Breastfeeding shouldn't automatically exclude you

Reduced circulating MOTS-c appears in obesity, type 2 diabetes, and aging, suggesting supplementation may restore youthful metabolic signaling capacity

Because these pens deliver fixed doses, using them for microdosing wastes medication (if you use a single pen across multiple weeks, you risk contamination, and the remaining medication goes to waste)

All groups were treated by gavage for 27 days

Research themes include pigmentation, neuronal repair, neuroendocrine signaling, and behavioral modulation

This pharmacokinetic profile supports once-weekly subcutaneous administration, delivered via prefilled autoinjector pens available in 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg per 0.5 mL dose strengths [54]